TY - JOUR
T1 - Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women.
AU - Villa, Paola
AU - Suriano, Rosanna
AU - Ricciardi, Luigi
AU - De Cicco, Simona
AU - Lanzone, Antonio
PY - 2011
Y1 - 2011
N2 - OBJECTIVE: To evaluate the effects of a daily E2 (1 mg) plus drospirenone oral formulation (2 mg) on glycoinsulinemic metabolism, lipid profile, and endothelial function in symptomatic healthy menopausal women.
DESIGN: Randomized, double-blind study.
SETTING: Operative Division of Endocrinological Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
PATIENT(S): Forty postmenopausal women.
INTERVENTION(S): Patients were randomly submitted to receive treatment with an oral dose of E2 (1 mg) plus drospirenone (2 mg) (group A) or placebo (group B).
MAIN OUTCOME MEASURE(S): Hormonal and lipid assessment; evaluation of glucose and insulin metabolism by the clamp test and the oral glucose tolerance test; evaluation of endothelial function by the vascular reactivity test.
RESULT(S): Total cholesterol levels, low-density lipoprotein cholesterol levels, and nonesterified fatty acids levels significantly decreased both after 3 and 6 months. No changes in high-density lipoprotein, triglycerides, apolipoprotein A1, apolipoprotein B, and lipoprotein (a) were found. Treatment resulted in few changes in glycoinsulinemic metabolism. We observed a significant reduction of the area under curve of insulin after 6 months of therapy. Endothelial function was significantly influenced by treatment, and an improvement in both flow-mediated dilatation and nitrate-mediated dilatation values after 6 months was observed.
CONCLUSION(S): Low-dose E2/drospirenone treatment did not reveal any negative effect on carbohydrate metabolism, acting in a neutral way on insulin sensitivity. The treatment induced favorable changes in lipid profile and showed a significant improvement of vascular reactivity.
AB - OBJECTIVE: To evaluate the effects of a daily E2 (1 mg) plus drospirenone oral formulation (2 mg) on glycoinsulinemic metabolism, lipid profile, and endothelial function in symptomatic healthy menopausal women.
DESIGN: Randomized, double-blind study.
SETTING: Operative Division of Endocrinological Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
PATIENT(S): Forty postmenopausal women.
INTERVENTION(S): Patients were randomly submitted to receive treatment with an oral dose of E2 (1 mg) plus drospirenone (2 mg) (group A) or placebo (group B).
MAIN OUTCOME MEASURE(S): Hormonal and lipid assessment; evaluation of glucose and insulin metabolism by the clamp test and the oral glucose tolerance test; evaluation of endothelial function by the vascular reactivity test.
RESULT(S): Total cholesterol levels, low-density lipoprotein cholesterol levels, and nonesterified fatty acids levels significantly decreased both after 3 and 6 months. No changes in high-density lipoprotein, triglycerides, apolipoprotein A1, apolipoprotein B, and lipoprotein (a) were found. Treatment resulted in few changes in glycoinsulinemic metabolism. We observed a significant reduction of the area under curve of insulin after 6 months of therapy. Endothelial function was significantly influenced by treatment, and an improvement in both flow-mediated dilatation and nitrate-mediated dilatation values after 6 months was observed.
CONCLUSION(S): Low-dose E2/drospirenone treatment did not reveal any negative effect on carbohydrate metabolism, acting in a neutral way on insulin sensitivity. The treatment induced favorable changes in lipid profile and showed a significant improvement of vascular reactivity.
KW - Drospirenone
KW - Drospirenone
UR - http://hdl.handle.net/10807/15118
M3 - Article
SN - 0015-0282
VL - 2011
SP - 158
EP - 163
JO - Fertility and Sterility
JF - Fertility and Sterility
ER -